Potential Drug Interactions of Repurposed COVID-19 Drugs with Lung Cancer Pharmacotherapies
재활용된 COVID-19 약물과 폐암 약물 요법의 잠재적 약물 상호 작용
Review
[키워드] adverse outcomes
anti-cancer treatment
Azithromycin
cancer patient
Care
ceftriaxone
Chemotherapy
Chloroquine
Comorbidity
Complication
concomitant treatment
concomitant treatments
COVID-19
COVID-19 infection
COVID-19 pandemic
Dexamethasone
dissemination
drug
Drug interactions
drug-drug interaction
Drug-drug interactions
Famotidine
Favipiravir
Healthcare professional
healthcare professionals
history of smoking
Hydroxychloroquine
identification
identify
Immunosuppression
information
kinase inhibitors
Lopinavir
Lopinavir/ritonavir
lung cancer
lung cancer patient
lung cancer patients
malignancy
management
medication
medications
occur
oseltamivir
outcome
Patient
pharmacotherapy
Potential
Prophylactic
proportion
QT prolongation
rationale
receiving
recent
Remdesivir
reported
Reporting
Repurposed drug
ribavirin
risk
risk factor
Ritonavir
sarilumab
severity
smoking
Tocilizumab
tyrosine
tyrosine kinase inhibitors
umifenovir
with COVID-19
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review
[DOI] 10.1016/j.arcmed.2020.11.006 PMC 바로가기 [Article Type] Review